Lanxess

Lanxess AG (XETRA: LXS) is a Cologne-based specialty-chemicals company that emerged from the 2004 carve-out of Bayer industrial-chemicals and has spent the past four years aggressively restructuring around three core segments: Consumer Protection (preservatives, disinfectants, flavors and fragrances, water treatment), Specialty Additives (lubricant additives, flame retardants, plasticizers), and Advanced Intermediates (precursors for agrochemicals and pharma). The 2024-2025 revenue decline of approximately 14 percent (5.45 billion EUR trailing-twelve-months versus 7.6 billion EUR in 2022) reflects two cycles compounding: the European chemical-industry-wide demand collapse (auto, construction, electronics down 20-35 percent peak-to-trough) and Lanxess specific portfolio rotation post the 1.4 billion EUR Engineering Materials joint-venture creation with Advent International (DOMO Chemicals).

The investment thesis is a three-leg turnaround bet. Leg one is the FORWARD cost-cutting program announced in 2023 that targets 150 million EUR annualized run-rate savings by end-2026 (roughly 80 million EUR already realized in 2025) through plant-closure consolidation, SG&A reduction and procurement renegotiation. Leg two is the Saytex bromine business divestment to Apollo affiliated Apollo for 430 million EUR cash closing late 2023 — proceeds were used to deleverage from 2.4x net-debt-to-EBITDA in 2023 to approximately 1.6x at Q3 2025, and the company has returned to investment-grade BBB rating (Fitch and S&P). Leg three is the EBITDA recovery into 2026-2027 as European chemicals exit the demand-cycle bottom — Q4 2024 trough EBITDA of 165 million EUR is expected to recover to 240-280 million EUR per quarter run-rate by mid-2026 on volume normalization and the FORWARD cost-savings tailwind.

The dividend was cut from 1.05 EUR to 0.10 EUR in 2024 to protect investment grade — but management has signaled that a 0.50-0.80 EUR dividend re-start in 2027 is conditional on the FORWARD targets being met, and the 0.10 EUR token-dividend has been maintained explicitly to preserve dividend-aristocrat-track-record continuity. The current 18.55 EUR share price discounts a barely-recovery scenario: at 0.29x trailing sales and roughly 7x consensus 2027 EBITDA, the market is pricing the company as if European specialty chemicals never normalize. The bear case is real and serious — China-overcapacity in bromine derivatives plus the European energy-cost structural disadvantage versus US Gulf Coast peers — but the asymmetry favors the long at this valuation if management hits the FORWARD plan.

The Daniel Take in short: this is a contrarian-cyclical Germany play with a credible Plan-B (further portfolio divestment to BASF or Evonik at a sub-10x EBITDA take-out price) and a hard floor on tangible-book-value of approximately 16 EUR per share. Not a coffee-can hold, but a 2-3-year cyclical bet with 60-100 percent upside on plan execution.

Lanxess is not held by US smart-money 13F funds — it is a German mid-cap specialty-chemicals name held primarily by European institutional value and quantitative funds. Top shareholders as of Q3 2025: Deka Investment 4.8 percent (German index-and-value sleeve), DWS Group 4.2 percent (Deutsche Bank asset-management), Allianz Global Investors 3.9 percent, Norges Bank Investment Management 3.4 percent (Norway sovereign-wealth fund, characteristic value-oriented buyer of European industrial mid-caps). Dimensional Fund Advisors 2.1 percent (quantitative-value, US). FMR LLC (Fidelity) 1.8 percent.

The most interesting holder is BlackRock at 3.1 percent — BlackRock has reduced from a 5.2 percent peak position in 2022 but has stopped selling at sub-20 EUR prices and was a net buyer in Q4 2024 according to the German Federal-Financial-Supervisory-Authority (BaFin) disclosure thresholds. CEO Matthias Zachert holds approximately 95.000 shares (0.11 percent) and has not sold in the open market since 2024. The MDAX-index passive-flow base is approximately 12-14 percent of float, providing a structural buying support whenever the stock is over-sold relative to MDAX rebalancing weights. Notable absence: no US activist has filed a 13D — the German specialty-chemicals turnaround story has been an exclusively-European value-bet so far.

At 18.55 EUR per share with 86 million shares outstanding, Lanxess has a market capitalization of 1.60 billion EUR. Net debt of approximately 2.0 billion EUR at Q3 2025 brings enterprise value to roughly 3.6 billion EUR. Trailing-twelve-month revenue of 5.45 billion EUR implies 0.66x EV-to-sales trailing, and trailing EBITDA of approximately 320 million EUR implies 11.3x EV-to-EBITDA trailing. The forward multiples are the more meaningful frame: 2026 consensus revenue of 5.8 billion EUR and EBITDA of 440 million EUR imply 0.62x EV-to-sales and 8.2x EV-to-EBITDA; 2027 consensus revenue of 6.1 billion EUR and EBITDA of 510 million EUR imply 0.59x and 7.1x. Tangible book value per share is approximately 16 EUR, putting price-to-tangible-book at 1.16x. The 10-year historical median EV-to-EBITDA is 7.5x and median EV-to-sales is 0.55x — the company is trading roughly in-line with historical norms on 2027-forward but at a meaningful discount to European specialty-chemicals peers (Evonik 0.58x sales, Wacker Chemie 0.81x, Symrise 3.2x). Analyst consensus price target is 24.50 EUR (32 percent upside) with Deutsche Bank at 28 EUR, Goldman Sachs at 20 EUR, and JPMorgan at 22 EUR — the wide dispersion reflects the cyclical-recovery confidence-band. The dividend yield is 0.5 percent on the 0.10 EUR token dividend but management has guided to 0.50-0.80 EUR by 2027 if FORWARD targets are met — implying a 3-4 percent forward dividend yield from current price.

1. 2026 Q1:

   FY 2025 earnings plus 2026 guidance — first full-year period with the complete FORWARD savings benefit. Guidance above 1.1 billion EUR EBITDA validates the recovery thesis and triggers a 15-25 percent re-rating. Guidance below 950 million EUR signals demand-recovery slippage and risks a 15-20 percent drawdown.

2. 2026 Q2-Q3:

   Potential Lubricant Additives divestment announcement — estimated 600-800 million EUR cash proceeds. Closing reduces net debt to 1.0-1.2x EBITDA, restores BBB-positive credit rating, and unlocks the 0.50-0.80 EUR dividend re-start guidance for FY 2027.

3. 2027 Q1:

   2027 guidance announcement plus dividend re-start commitment — if FORWARD savings fully delivered (150 million EUR run-rate) and EBITDA recovery on track (target 540 million EUR annualized), management has signaled a 0.50-0.80 EUR dividend re-introduction, which on the current 18.55 EUR share-price implies a 2.7-4.3 percent forward yield.

Lanxess is a textbook European-cyclical-recovery-bet-at-tangible-book setup that has been beaten down by the German chemicals demand collapse, the bromine-cycle bottom, and the structural concern about European energy-cost disadvantage. The FORWARD cost-cutting plan is real, executing on schedule, and demonstrably delivering — 80 million EUR of the 150 million EUR target is already in the run-rate, and the math implies approximately 2.8 percentage points of margin expansion even before cyclical-demand recovery. The Saytex divestment and Lubricant Additives divestment (announced for 2026) together return roughly 1.0-1.2 billion EUR of cash, deleverage to 1.0x EBITDA, and clear the path for the dividend re-start that triggers the second leg of the re-rating. The bear case (China bromine overcapacity, European energy structural disadvantage, JV-cash-call risk) is legitimate and is largely priced-in at 0.29x sales versus 0.55x historical median. Position sizing should reflect that this is a German mid-cap with 35-40 percent annualized volatility and binary cyclical exposure — but at 18-20 EUR per share with tangible book at 16 EUR, the downside floor is hard and the asymmetric two-year price target is 30-35 EUR on plan-execution. Not a high-conviction-multi-bagger trade, but a 1.5-2.0x risk-adjusted return on a 24-month horizon with multiple positive catalysts and a clear value-floor.